Cell Therapeutics Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 8 Calls Today's Calls

Call Details Cell Therapeutics Earnings Conference Call (Q1 2008) Thu, May 8, 2008, 8:30 am Eastern Listen to the archived event audio About Cell Therapeutics (NasdaqGM:CTIC) Cell Therapeutics, Inc. markets lymphoma drug, Zevalin, in the United States. Zevalin is an FDA-approved radioimmunotherapeutic for treating lymphoma. The company also develops, acquires, and commercializes novel treatments for cancer. In addition, Cell Therapeutics develops XYOTAX for the treatment of non-small cell lung cancer and ovarian cancer; Pixantrone, a novel compound in the class of drugs known as anthracyclines, for non-Hodgkin’s lymphoma; and Brostallicin, which is in first-line Phase II study for the treatment of sarcoma. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd. and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings